Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial is a Phase I study, which means it was primarily designed to test safety and tolerability rather than whether KP405 actually helps with Parkinson's symptoms — does that match what I need right now, or should I be looking at trials in a later phase?
2. 2The trial monitored things like heart rhythms, blood pressure, and injection site reactions — what does that tell us about the kinds of side effects or risks that were being watched for with KP405, and are there any signals I should be aware of?
3. 3Since this trial has already completed and involved both healthy volunteers and Parkinson's patients, has safety and tolerability data been published yet, and how would that information guide whether KP405 might be appropriate for me to consider?
4. 4The trial measured injection site reactions as a primary outcome, which suggests KP405 is given by injection — how does that fit my current daily routine and health situation, and is that a realistic option for me?
5. 5Given that this was an early Phase I study focused on safety rather than effectiveness, what would the next step look like — is there a Phase II or III trial testing whether KP405 actually improves Parkinson's symptoms that might be worth discussing as an option?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.